Literature DB >> 26623053

Mutational analysis of the insulin-like growth factor 1 receptor tyrosine kinase domain in non-small cell lung cancer patients.

Kathy Gately1, Lydia Forde1, Stephen Gray1, Derek Morris2, Aidan Corvin3, Prerna Tewari4, Kenneth O'Byrne5.   

Abstract

The insulin-like growth factor 1 receptor (IGF1R) pathway plays an important role in the pathogenesis of non-small cell lung cancer (NSCLC) and also provides a mechanism of resistance to targeted therapies. IGF1R is therefore an ideal therapeutic target and several inhibitors have entered clinical trials. However, thus far the response to these inhibitors has been poor, highlighting the importance of predictive biomarkers to identify patient cohorts who will benefit from these targeted agents. It is well-documented that mutations and/or deletions in the epidermal growth factor receptor (EGFR) tyrosine kinase (TK) domain predict sensitivity of NSCLC patients to EGFR TK inhibitors. Single-nucleotide polymorphisms (SNPs) in the IGF pathway have been associated with disease, including breast and prostate cancer. The aim of the present study was to elucidate whether the IGF1R TK domain harbours SNPs, somatic mutations or deletions in NSCLC patients and correlates the mutation status to patient clinicopathological data and prognosis. Initially 100 NSCLC patients were screened for mutations/deletions in the IGF1R TK domain (exons 16-21) by sequencing analysis. Following the identification of SNP rs2229765, a further 98 NSCLC patients and 866 healthy disease-free control patients were genotyped using an SNP assay. The synonymous SNP (rs2229765) was the only aberrant base change identified in the IGF1R TK domain of 100 NSCLC patients initially analysed. SNP rs2229765 was detected in exon 16 and was found to have no significant association between IGF1R expression and survival. The GA genotype was identified in 53.5 and 49.4% of NSCLC patients and control individuals, respectively. No significant difference was found in the genotype (P=0.5487) or allele (P=0.9082) frequencies between the case and control group. The present findings indicate that in contrast to the EGFR TK domain, the IGF1R TK domain is not frequently mutated in NSCLC patients. The synonymous SNP (rs2229765) had no significant association between IGF1R expression and survival in the cohort of NSCLC patients.

Entities:  

Keywords:  insulin-like growth factor 1 receptor; non-small cell lung cancer; single-nucleotide polymorphism; targeted therapy

Year:  2015        PMID: 26623053      PMCID: PMC4534863          DOI: 10.3892/mco.2015.580

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  41 in total

1.  The international system for staging lung cancer.

Authors:  C F Mountain
Journal:  Semin Surg Oncol       Date:  2000-03

2.  Studies of the variability of the genes encoding the insulin-like growth factor I receptor and its ligand in relation to type 2 diabetes mellitus.

Authors:  S K Rasmussen; C Lautier; L Hansen; S M Echwald; T Hansen; C T Ekstrøm; S A Urhammer; K Borch-Johnsen; F Grigorescu; R J Smith; O Pedersen
Journal:  J Clin Endocrinol Metab       Date:  2000-04       Impact factor: 5.958

3.  Polymorphic variants of insulin-like growth factor I (IGF-I) receptor and phosphoinositide 3-kinase genes affect IGF-I plasma levels and human longevity: cues for an evolutionarily conserved mechanism of life span control.

Authors:  Massimiliano Bonafè; Michelangela Barbieri; Francesca Marchegiani; Fabiola Olivieri; Emilia Ragno; Claudia Giampieri; Elena Mugianesi; Matteo Centurelli; Claudio Franceschi; Giuseppe Paolisso
Journal:  J Clin Endocrinol Metab       Date:  2003-07       Impact factor: 5.958

4.  A comprehensive in silico analysis of the functional and structural impact of SNPs in the IGF1R gene.

Authors:  S A de Alencar; Julio C D Lopes
Journal:  J Biomed Biotechnol       Date:  2010-06-23

5.  Insulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small-cell lung cancer (NSCLC) patients.

Authors:  F Cappuzzo; G Tallini; G Finocchiaro; R S Wilson; C Ligorio; L Giordano; L Toschi; M Incarbone; R Cavina; L Terracciano; M Roncalli; M Alloisio; M Varella-Garcia; W A Franklin; A Santoro
Journal:  Ann Oncol       Date:  2009-09-18       Impact factor: 32.976

6.  A polymorphic variant of the insulin-like growth factor type I receptor gene modifies risk of obesity for esophageal adenocarcinoma.

Authors:  Kimberley MacDonald; Geoffrey A Porter; Duane L Guernsey; Ronghua Zhao; Alan G Casson
Journal:  Cancer Epidemiol       Date:  2009-05-28       Impact factor: 2.984

7.  High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients.

Authors:  V Ludovini; G Bellezza; L Pistola; F Bianconi; L Di Carlo; A Sidoni; A Semeraro; R Del Sordo; F R Tofanetti; M G Mameli; G Daddi; A Cavaliere; M Tonato; L Crinò
Journal:  Ann Oncol       Date:  2009-01-19       Impact factor: 32.976

8.  Heterodimerization of glycosylated insulin-like growth factor-1 receptors and insulin receptors in cancer cells sensitive to anti-IGF1R antibody.

Authors:  Jun Gyu Kim; Min Jueng Kang; Young-Kwang Yoon; Hwang-Phill Kim; Jinah Park; Sang-Hyun Song; Sae-Won Han; Jong-Wan Park; Gyeong Hoon Kang; Keon Wook Kang; Do Youn Oh; Seock-Ah Im; Yung-Jue Bang; Eugene C Yi; Tae-You Kim
Journal:  PLoS One       Date:  2012-03-16       Impact factor: 3.240

9.  High expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507).

Authors:  Yixuan Gong; Evelyn Yao; Ronglai Shen; Aviva Goel; Maria Arcila; Julie Teruya-Feldstein; Maureen F Zakowski; Stanley Frankel; Martin Peifer; Roman K Thomas; Marc Ladanyi; William Pao
Journal:  PLoS One       Date:  2009-10-06       Impact factor: 3.240

10.  Clinical significance of insulin-like growth factor-1 receptor expression in stage I non-small-cell lung cancer: immunohistochemical analysis.

Authors:  Chang Youl Lee; Jeong Hee Jeon; Hyung Jung Kim; Dong Hwan Shin; Tae Woong Roh; Chul Min Ahn; Yoon Soo Chang
Journal:  Korean J Intern Med       Date:  2008-09       Impact factor: 2.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.